<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" public-private="public" dms-id="HA7B41E0AFBA041DF8263DF2BA5AB8D66"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 5768 IH: Skin Substitute Access and Payment Reform Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-10-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5768</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20251017">October 17, 2025</action-date><action-desc><sponsor name-id="C001103">Mr. Carter of Georgia</sponsor> (for himself, <cosponsor name-id="V000131">Mr. Veasey</cosponsor>, <cosponsor name-id="S001214">Mr. Steube</cosponsor>, and <cosponsor name-id="M001218">Mr. McCormick</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.</official-title></form><legis-body id="H044D6852A8594156ABBBAF7346A35E5C"><section id="HF868A671078348A0992072C282D554AC" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Skin Substitute Access and Payment Reform Act</short-title></quote>.</text></section><section id="HED8319E594504A21B51919C5C214353F"><enum>2.</enum><header>Payment reform for skin substitute products</header><subsection id="H1C7FAEB0962040D5B0F95F07B824DE96"><enum>(a)</enum><header>Coverage of skin substitute products</header><text>Section 1861(s)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(s)(2)</external-xref>) is amended—</text><paragraph id="H6963876B6FE04E13A0147A97D73CF401"><enum>(1)</enum><text>in subparagraph (JJ), by adding <quote>and</quote> at the end; and</text></paragraph><paragraph id="H3721065D420843AC89997DB5C336F9A3"><enum>(2)</enum><text>by inserting after subparagraph (JJ) the following new subparagraph:</text><quoted-block id="H6CD3B0A8840A457E8BFEBF125EF4D154" style="OLC"><subparagraph id="HA6A09C4707134A8EAED1B0E0E44DA82A"><enum>(KK)</enum><text>skin substitute products (as defined in section 1847A(c)(6)(J)).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HC598F2B7C1CE403BAEB74645BDC1691A"><enum>(b)</enum><header>Payment</header><paragraph id="HDCE9F692663F410AB1D62D039D5C8ECC"><enum>(1)</enum><header>Payment amount</header><text>Section 1847A of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-3a">42 U.S.C. 1395w–3a</external-xref>) is amended—</text><subparagraph id="H5C6A9BE123ED4D4D9A97B538B02EF6B9"><enum>(A)</enum><text>in subsection (a)(1)—</text><clause id="H2CEAD080783D43C881B36AEA1805E086"><enum>(i)</enum><text>by striking the period at the end and inserting <quote>; and</quote>;</text></clause><clause id="H9B8BFE36EE39462285367BDBBE27DA68"><enum>(ii)</enum><text>by striking <quote>shall apply to</quote> and inserting </text><quoted-block id="HCE2AE6055E5042E5A4C3C7355D906DF5" style="OLC" display-inline="yes-display-inline"><text>shall apply—</text><subparagraph id="HBCFB387337434628B2D7291A1FA3ED56"><enum>(A)</enum><text>to</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></clause><clause id="H4A3B3642C6194B9CBA0B27063327C69C"><enum>(iii)</enum><text>by adding at the end the following new subparagraph:</text><quoted-block id="HB78C4C1BCF594490A9914CB560F9DC90" style="OLC"><subparagraph id="HE5C26305607F4381876E789E83179286"><enum>(B)</enum><text>to payment for skin substitute products (as defined in subsection (c)(6)(J)) that are furnished on or after January 1, 2026.</text></subparagraph><after-quoted-block>;</after-quoted-block></quoted-block></clause></subparagraph><subparagraph id="HC5AE5F8E3AE848519359F665A307FC29"><enum>(B)</enum><text>in subsection (b)—</text><clause id="H191504DA72634DE88D1E86999308D2EF"><enum>(i)</enum><text>in paragraph (1)—</text><subclause id="HFBE15608CAB94B269A311A620BFB642C"><enum>(I)</enum><text>in the text preceding subparagraph (A), by inserting <quote>or a skin substitute product</quote> after <quote>drug or biological</quote>;</text></subclause><subclause id="HD824D45C52EF4FF18B77077E0C8A3908"><enum>(II)</enum><text>in subparagraph (B), by striking <quote>or</quote> at the end;</text></subclause><subclause id="H82F86A57EF514532BCCEA0419F22F7A9"><enum>(III)</enum><text>in subparagraph (C), by striking the period at the end and inserting <quote>; or</quote>; and</text></subclause><subclause id="H07AE841D17FE4A28B68B461A01A20DDF"><enum>(IV)</enum><text>by adding at the end the following new subparagraph:</text><quoted-block id="H0C47187DE7D24025A0E54E772A1CF46D" style="OLC"><subparagraph id="HA37CC0AFCECE4557B338AA3600310D92"><enum>(D)</enum><text>in the case of a skin substitute product (as defined in subsection (c)(6)(J)), the amount determined under paragraph (9).</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subclause></clause><clause id="HB209A39E64EB47BCBAD1EF3AFB44C669"><enum>(ii)</enum><text>in paragraph (2)—</text><subclause id="H29A4AABBE3B144AAB44CCEC0D2CCD4F4"><enum>(I)</enum><text>in subparagraph (A), by inserting <quote>or a skin substitute product</quote> after <quote>drug or biological</quote>; and</text></subclause><subclause id="H7AB812FDB17943B88F2BB7C44A96AA77"><enum>(II)</enum><text>in subparagraph (B), by inserting <quote>, and, with respect to a skin substitute product, a square centimeter</quote> after <quote>pertaining to liquids</quote>; and</text></subclause></clause><clause id="H428A22BC70004081A89818BDEDAFE91F"><enum>(iii)</enum><text>by adding at the end the following:</text><quoted-block id="H7D81C962E03C45E2B3DA9AD699306432" style="OLC"><paragraph id="H3AFEF269F63949F99C4A06DAB76DF88C"><enum>(9)</enum><header>Skin substitute products</header><subparagraph id="H7F1050D4BAC947A4B80531FE0F1F27CB"><enum>(A)</enum><header>Payment amount</header><clause id="H79FEF75C842A4CECB55A5846C6F2573A"><enum>(i)</enum><header>Initial payment amount</header><text>For 2026, the amount determined under this paragraph for a skin substitute product is the volume-weighted average of the Medicare payment allowance limits for skin substitute products, as determined under subparagraph (B).</text></clause><clause id="H1B37F3CDE19140AAA73D0B82DB6585F4"> <enum>(ii)</enum> <header>Annual update</header> <text>For 2027 and each subsequent year, the amount determined under this paragraph for a skin substitute product for such year is equal to the amount determined under this paragraph for the previous year, adjusted by the percentage increase in the Consumer Price Index for All Urban Consumers (United States city average) for the 12-month period ending with June of such previous year.</text>
 </clause></subparagraph><subparagraph id="H9C25A4FEA70B4A96B6948E82C3B49F07"><enum>(B)</enum><header>Volume-weighted average payment limit</header><text>For purposes of subparagraph (A)(i), the volume-weighted average of the Medicare payment allowance limits for skin substitute products is determined by—</text><clause id="HAFC4068EB5694D47AF728868100B2CBE"><enum>(i)</enum><text>calculating, with respect to each billing and payment code listed in the October 2023 ASP Pricing File for each skin substitute product, an amount equal to the product of—</text><subclause id="H8DA06B7C5B324D38B42F3EC8D5D60C8A"><enum>(I)</enum><text>the payment limit included in such file with respect to such code; and</text></subclause><subclause id="H54B5D11FAB9D48759FE8131500BC9A6C"><enum>(II)</enum><text>the number of units (as specified under paragraph (2))—</text><item id="H9B820E8CDB48454486848B33E9D16501"><enum>(aa)</enum><text>billed with respect to such code for a date of service in 2023; and</text></item><item id="H2460F310425749AF8D04EE65F348BCE2"><enum>(bb)</enum><text>listed in the CMS Integrated Data Repository for Part B (Carrier &amp; DME) claims data;</text></item></subclause></clause><clause id="HD5EAD3133203450C8384C563A4D7A6CB"><enum>(ii)</enum><text>calculating the sum of all amounts determined under clause (i); and</text></clause><clause id="H983C36B2B33B4A21A3172651FCA1B23C"><enum>(iii)</enum><text>dividing the sum calculated under clause (ii) by the total number of units determined under clause (i)(II).</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></clause></subparagraph></paragraph><paragraph id="H171E2EB0AFEC4DF3AC7E3BA0804AD98B"><enum>(2)</enum><header>Conforming amendments</header><text>Section 1833(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(a)(1)</external-xref>) is amended—</text><subparagraph id="H61D7BA09B67443498E575AA0B0DDE2B3"><enum>(A)</enum><text>in subparagraph (S)(i), by striking <quote>subject to subparagraph (EE)</quote> and inserting <quote>subject to subparagraphs (EE) and (II)</quote>;</text></subparagraph><subparagraph id="H6F783300BC3C42AEB34EE559E77266F1"><enum>(B)</enum><text>by striking <quote>and (HH)</quote> and inserting <quote>(HH)</quote>; and</text></subparagraph><subparagraph id="H31EA3AE5487A4F1E93CBF0F8F5D67C40"><enum>(C)</enum><text>by inserting <quote>, and (II) with respect to skin substitute products under section 1861(s)(2)(KK), the amount paid shall be 80 percent of the lesser of the actual charge or the payment amount established under section 1847A(b)(9)</quote> before the semicolon at the end.</text></subparagraph></paragraph></subsection><subsection id="HB56A3B55BCB74E84976FAC8DD87934E2"><enum>(c)</enum><header>Skin substitute product defined</header><text>Section 1847A(c)(6) of the Social Security Act (42 U.S.C. 1395w–3a(c)(6)) is amended by adding at the end the following:</text><quoted-block id="H926CA65B1ED64762B806B35690B58376" style="OLC"><subparagraph id="H2C7810F96F764D25A5C7DAD4EFD5A0C6"><enum>(J)</enum><header>Skin substitute products</header><text>The term <quote>skin substitute product</quote>—</text><clause id="HCF79C568DE1F44B88454BBEAF36389F8"><enum>(i)</enum><text>means a cellular, tissue, biological or synthetic material that—</text><subclause id="H7D78CF429D8642F5B388B1DBE1C95135"><enum>(I)</enum><text>is applied to a wound and intended to remain within the wound bed; and</text></subclause><subclause id="H4F49E8275588479C803CDFD90CFAE268"><enum>(II)</enum><text>is marketed pursuant to section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act, or section 361 of the Public Health Service Act; and</text></subclause></clause><clause id="H667B32A7A225453BB3253C5A5FCFA416"><enum>(ii)</enum><text>does not include—</text><subclause id="HEA75C7AAD68E442EBF33EB2626A7E8C4"><enum>(I)</enum><text>a product that is intended to temporarily protect or cover the wound bed and be removed before complete resorption (such as a dressing); or</text></subclause><subclause id="HC20FD8AA50174739B1E4D1E44B613389"><enum>(II)</enum><text>a liquid, gel, powder, or other similarly constituted item.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HA6D1B3F127F7478B9FE5178469518E4D"><enum>(d)</enum><header>Exclusion from reporting requirements</header><text>Section 1847A(f)(2)(A) of the Social Security Act (42 U.S.C. 1395w–3a(f)(2)(A)) is amended by inserting <quote>(except that, beginning January 1, 2026, a drug or biological so described does not include a skin substitute product (as defined in subsection (c)(6)(J)))</quote> after <quote>products that are payable under this part as a drug or biological</quote>.</text></subsection><subsection id="HFC8D4AAA139D40A79E91E41CB58C3581"><enum>(e)</enum><header>Consolidated billing and payment code</header><text>Not later than January 1, 2026, the Secretary of Health and Human Services shall establish a new billing and payment code for all skin substitute products (as defined in subparagraph (J) of section 1847A(c)(6) of the Social Security Act (42 U.S.C. 1395w–3a(c)(6)), as added by subsection (b)).</text></subsection></section><section id="HD1FA6731BE8644389EC2415CACD07A1B"><enum>3.</enum><header>Enhancing program integrity for skin substitute products</header><text display-inline="no-display-inline">Section 1834 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m</external-xref>) is amended by adding at the end the following new subsection:</text><quoted-block id="H44CA5ECCC3A242B9932F9779B5658E90" style="OLC"><subsection id="H1A230FF2559C4E22A3129A3A7B752640"><enum>(aa)</enum><header>Special payment rules for skin substitute products</header><paragraph id="HEDC64DD19E3E4ADAB617ABCAE7DBFC3F"><enum>(1)</enum><header>Identification of outlier providers of skin substitute products</header><subparagraph id="H62806267D62B47EB9F4A94EDB6974686"><enum>(A)</enum><header>In general</header><text>Not later than December 1, 2025, and every 2 years thereafter through December 1, 2035, the Secretary shall determine the 3 percent of the total number of providers of skin substitute products that are outlier providers of skin substitute products.</text></subparagraph><subparagraph id="H46856AC19250416A9D6E12478358C472"><enum>(B)</enum><header>Outlier providers of skin substitute products</header><text>The determination of an outlier provider of skin substitute products under this paragraph shall be based upon the providers (as identified by national provider identification number) that received the greatest total payment under this title for skin substitute products furnished in the year preceding the year in which the determination under subparagraph (A) is made.</text></subparagraph><subparagraph id="H6EC491CB82C84C159AAB4526EB533F7F"><enum>(C)</enum><header>Referral to oig</header><text>The Secretary shall—</text><clause id="H8DDD5F7688E8426599AD3E57107AA712"><enum>(i)</enum><text>make publicly available the list of outlier providers of skin substitute products identified under each determination under subparagraph (A); and</text></clause><clause id="HF0F68F6037D54EA0A60E55E6B92A62F4"><enum>(ii)</enum><text>transmit such list to the Inspector General of the Department of Health and Human Services for the assessment of potential fraud, waste, or abuse.</text></clause></subparagraph></paragraph><paragraph id="HE032866A1658424296683A867A53B5A8"><enum>(2)</enum><header>Initial prepayment claim review for certain outlier providers</header><subparagraph id="H4EFA2182F76F453AA2D94649DDD01B8A"><enum>(A)</enum><header>In general</header><text>Beginning January 1, 2026, the Secretary shall conduct prepayment review of claims for skin substitute products submitted under this title by an outlier provider of skin substitute products unless 1 or more of the conditions described in subparagraph (B) is met with respect to such provider.</text></subparagraph><subparagraph id="H5062E0EF2F99409BBCB2FE4FB907CB95"><enum>(B)</enum><header>Limitation</header><text>For purposes of subparagraph (A), the conditions described in this subparagraph are, with respect to an outlier provider of skin substitute products, the following:</text><clause id="H36EDBF0961ED4914A65390599163C7D8"><enum>(i)</enum><text>Skin substitute products furnished by the provider are subject to prior authorization under paragraph (3).</text></clause><clause id="H8E99ADDD4D3A4A0CAD022B31B66CF50B"><enum>(ii)</enum><text>The rate of approval for claims for skin substitute products furnished by such provider that are subject to prepayment review under this paragraph exceeds 90 percent (as determined over a period of time or number of claims specified by the Secretary).</text></clause><clause id="HF21F7D6CCFDD44E6BEE4D562628E442A"><enum>(iii)</enum><text>The Secretary determines that the billing practices of the provider are consistent with the applicable coverage criteria and requirements under this title.</text></clause></subparagraph></paragraph><paragraph id="HEB70EA4BC672457085937818700A3468"><enum>(3)</enum><header>Prior authorization for outlier providers of skin substitute products</header><subparagraph id="H37265CB8EEF14363B4CBFCFDA80CEA17"><enum>(A)</enum><header>In general</header><text>Beginning not later than January 1, 2027, subject to subparagraph (B), the Secretary shall, for a period determined appropriate by the Secretary, apply prior authorization for skin substitute products that are furnished by an outlier provider of skin substitute products identified under paragraph (1).</text></subparagraph><subparagraph id="H837E35D47FB04F0992EB11B5239581E8"><enum>(B)</enum><header>Removal from prior authorization</header><text>In the event that the Secretary determines, with respect to an outlier provider of skin substitute products, that the rate of approval for requests for prior authorization under this paragraph for skin substitute products furnished by such provider exceeds 90 percent (as determined over a period of time or number of claims specified by the Secretary), the Secretary shall cease to apply prior authorization under this paragraph for skin substitute products furnished by such provider.</text></subparagraph><subparagraph id="H26D5DB7B76134DC987C77FCC67052B88"><enum>(C)</enum><header>Funding</header><text>For purposes of carrying out this paragraph, the Secretary shall provide for the transfer, from the Federal Supplementary Medical Insurance Trust Fund under section 1841, to the Centers for Medicare &amp; Medicaid Services Program Management Account, of $5,000,000 for each of fiscal years 2027 through 2030, to remain available until expended.</text></subparagraph></paragraph><paragraph id="H647AA0EC5B4D4A4E9ECFFB84E1BDE772"><enum>(4)</enum><header>Enrollment revocation or exclusion of noncompliant outlier providers</header><subparagraph id="HDEBA9351F4BC462F9763D2F767351773"><enum>(A)</enum><header>In general</header><text>Beginning January 1, 2028, if the rate of denial for requests for prior authorization under paragraph (3) for skin substitute products furnished by an outlier provider of skin substitute products exceeds 75 percent over a period of 6 or more consecutive months, the Secretary shall determine that an abuse of billing privileges exists with respect to such provider for purposes of section 424.535(a)(8)(ii) of title 42, Code of Federal Regulations.</text></subparagraph><subparagraph id="H8F2722B5CE9548C4AD2C458A4B4F90CF"><enum>(B)</enum><header>Referral for exclusion</header><text>If the Secretary determines under subparagraph (A) that an abuse of billing privileges exists with respect to an outlier provider of skin substitute products, the Secretary shall direct the Inspector General of the Department of Health and Human Services to determine whether such provider should be excluded from participation in any Federal health care program under section 1128(b)(6).</text></subparagraph></paragraph><paragraph id="HAECDA497ECAC496981F007FF1E346F92"><enum>(5)</enum><header>Medicare coverage criteria for skin substitute products</header><text>Any skin substitute product defined in section 1847A(c)(6)(J) of the Social Security Act and furnished during 2026 shall be subject to the same coverage criteria when determining whether the skin substitute product is covered under section 1862(a)(1)(A), unless such product is determined by the Secretary to be unsafe based on evidence of contamination, serious infectious disease, or serious adverse reactions caused by the product. Neither the Secretary nor any Medicare administrative contractor may determine, including through a determination made pursuant to the prepayment review program or prior authorization program described in paragraphs (2) and (3), that a specific skin substitute product furnished in 2026 is not covered by Medicare based solely on analysis of the clinical evidence relating to that skin substitute product.</text></paragraph><paragraph id="HDCBF6C4EFABB4003AEB966F852827A69"><enum>(6)</enum><header>Skin substitute product defined</header><text>In this subsection, the term <quote>skin substitute product</quote> has the meaning given such term in section 1847A(c)(6)(J).</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

